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Medulloblastoma is the most common malignant
brain tumour in childhood and accounts for 15–
20% of central nervous system (CNS) neoplasms.
It was first described in 1925 by Bailey and
Cushing as a tumour of primitive origin arising in
the posterior fossa of young children.
Medulloblastoma has strong common clinical
characteristics with histologically similar tumours
occurring elsewhere in the CNS, leading to the
concept of primitive neuroectodermal tumours
(PNETs) in 1973.1 This term included both
medulloblastoma (80% of PNETs) and tumours
occurring in the supratentorial region of the brain.
Although the concept of PNETs was generally
accepted, there is growing doubt as to whether
PNETs arise from a common cell of origin, with
increasing evidence of differences between the
molecular characteristics of medulloblastoma and
supratentorial PNETs.2 In this respect, the term
medulloblastoma describing a distinct entity is
generally preferred to posterior fossa PNET.
The large majority of medulloblastomas occur
within the first decade of life with a peak incidence
between 4 and 7 years of age. However, cases in
adolescence and indeed adulthood are well
described. There is an approximately 1.7:1 male
to female ratio. There is a suggestion that the
incidence of PNETs in persons under 20 years of
age is increasing to now lie at around five per 106
person years.3 This equates to around 90 patients
diagnosed with medulloblastoma in the UK each
year.
By definition, a medulloblastoma arises in the
posterior fossa, usually from the cerebellar vermis
in the roof of the fourth ventricle, thus presenting
as a midline tumour (fig 1). A smaller proportion of
cases arise in a cerebellar hemisphere, particularly
in older children. Medulloblastomas have a marked
propensity to seed within the cerebrospinal fluid
(CSF) pathways, with evidence of such metastatic
spread occurring in up to 35% of cases at
diagnosis.4 In addition, there is evidence of meta-
static spread outside the CNS, with, for example,
bone or bone marrow disease (stage M4) in less
than 5% of cases.
INHERITED GENETIC PREDISPOSITION TO
MEDULLOBLASTOMA
The vast majority of medulloblastomas arise
sporadically, but a small proportion of cases
(,5%) are associated with familial predisposition
caused by inherited germline mutations. Thus,
medulloblastomas arise as a feature of Li-Fraumeni,
Turcot and Gorlin syndromes, which are caused by
germline mutations in the TP53, APC and PTCH
genes, respectively. This has led to the consequent
identification of significant roles for these genes,
and the associated biological pathways in which
their encoded proteins function (APC in the Wnt/
Wingless signalling pathway, PTCH in the Sonic
hedgehog signalling pathway), in sporadic medul-
loblastoma development.5
THE HISTOPATHOLOGY OF MEDULLOBLASTOMA
About 80% of medulloblastomas are described as
having a classic phenotype, being composed of
sheets of generally small round cells with little
cytoplasm and frequent mitoses.6 Various degrees
of glial or neuronal differentiation may be seen.
The desmoplastic variant is most notably seen in
very young children, where it occurs in up to 50%
of tumours, and has been associated with an
improved outcome.7 8 In children over 3 years of
age at diagnosis, desmoplasia is less common (,5%
of cases) and the significance of this histological
subtype appears less important, possibly as the use
of more intensive treatment including radiother-
apy may offset the impact of improved outcome in
older patients.8 Widespread and severe anaplasia,
characterised by cytologic pleomorphism and a
high mitotic count, is seen in about 15% of cases
and is associated with a poorer prognosis.6 9 10 The
rare large-cell medulloblastoma accounts for about
5% of cases and has clearly been associated with a
worse outcome.6 9 10
Based on these histological phenotypes and
differences in their clinical behaviours (table 1),
the current WHO classification of CNS tumours
defines the following histopathological variants
of medulloblastoma: (i) classic medulloblastoma,
(ii) desmoplastic/nodular medulloblastoma,
(iii) medulloblastoma with extensive nodularity,
(iv) anaplastic medulloblastoma (if anaplasia is
severe and diffuse) and (iv) large-cell medulloblas-
toma.11
THE BIOLOGY OF MEDULLOBLASTOMA
DEVELOPMENT
Although no characteristic cytogenetic or molecu-
lar abnormality has been identified which defines
medulloblastoma, a series of critical genetic
abnormalities have been characterised which offer
potential for improved disease stratification and
the development of novel therapeutic approaches.
The Wnt/Wingless (Wnt/Wg) and Sonic hedge-
hog (SHH) signalling pathways are both essential
in normal neural and cerebellar development12 13
and become aberrantly activated by genetic mutation
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in subsets of medulloblastomas. Activation of the
Wnt/Wg and SHH pathways appears to define
mutually exclusive subgroups of tumours and
occurs in about 15% and 25% of cases, respec-
tively.14 SHH activation has been associated with
the desmoplastic histopathological subtype15 but is
also observed in other histological types. To date,
however, studies have not found that activation of
the SHH pathway or associated defects (ie, 9q loss)
is prognostically significant.16 17
Wnt/Wg pathway activation appears to define a
unique molecular subgroup of medulloblastomas
which has a distinctive and characteristic biology
in terms of patterns of gene expression and
genomic abnormalities.14 18 Moreover, Wnt/Wg-
active medulloblastomas are associated with dis-
tinctively favourable clinical behaviour. b-Catenin
status (a marker of Wnt/Wg pathway activation)
is an independent marker of good outcome (ie,
greater than 90% survival), as observed in several
clinical trial-based studies16 19 (fig 2).
The most prevalent chromosomal abnormality
seen in medulloblastoma is isochromosome 17q
(30–50% of cases), while losses of chromosomes 8,
9, 10q, 11, 16q and 17p and gains of chromosomes
7 and 17q are also commonly observed (each in
.20% of cases).15 MYC and MYCN are the most
commonly amplified genes (each in about 5% of
cases) and have been associated with large-cell and
anaplastic medulloblastomas and a poor out-
come.9 17
CLINICAL PRESENTATION
Most patients present with signs and symptoms of
raised intracranial pressure due to hydrocephalus
following obstruction of the CSF pathways at the
level of the fourth ventricle and the aqueduct of
Sylvius. Thus headaches, vomiting, lethargy and
drowsiness together with papilloedema occur in
around 80% of patients at diagnosis. Although
most patients present acutely, the diagnosis can
often be delayed for several months. Other
presenting features include ataxia due to cerebellar
involvement and diplopia, cranial nerve palsies and
long tract signs as a result of pressure on or
infiltration of the brain stem. Occasionally patients
may present with manifestations of spinal metas-
tases such as back pain or lower limb weakness.
Very young children may present with irritability,
widening of the cranial sutures, increasing head
circumference or the ‘‘setting sun’’ sign.
PROGNOSTIC FEATURES AND STAGING
The outcome for children with medulloblastoma is
closely related to the age of the patient and the
extent of disease at diagnosis (table 1). The clearly
worse prognosis in very young children is partly
related to the avoidance of radiotherapy, particu-
larly craniospinal radiotherapy (CSRT), because of
the severe neurological sequelae of cranial radio-
therapy for the young developing brain. Thus,
recent therapy in children aged less than 3–6 years
has focused on the use of specific protocols, as
discussed below, in order to delay or avoid the use
of CSRT.
The presence of metastatic disease at presenta-
tion on MRI of the brain (Chang stage M2) or
spine (stage M3) clearly confers a poor prog-
nosis.4 20 The prognostic significance of stage M1
disease, in which tumour cells are found within the
CSF without radiological evidence of metastasis, is
less clearly defined, although it is now accepted by
both the North American Children’s Oncology
Group (COG) (previously the Children’s Cancer
Group (CCG) and the Paediatric Oncology Group
(POG)) and the European SIOP (International
Society of Paediatric Oncology) group that patients
with M1 disease have a poorer prognosis than
those without evidence of such tumour spread,20
albeit with an outcome better than with stage M2/
3 disease.
Thus a careful metastatic evaluation with non-
enhanced and contrast enhanced MRI of the brain
and spine is a critical component of management.
The recent COG A9961 trial demonstrated an
increased failure rate in patients with overlooked
M2 or M3 disease in a central radiology review.21 In
addition, CSF should be examined for tumour cells
following recovery from surgery. CSF taken by
Figure 1 Medulloblastoma: T1-weighted sagittal MRI
scan following gadolinium administration. Image kindly
provided by Dr Simon Bailey.
Table 1 Medulloblastoma: currently accepted
prognostic factors
Favourable risk
Histology Desmoplasia in patients ,3 years old7 8
Biology Wnt/Wg pathway activation (b-catenin
nuclear stabilisation)16 19
Adverse risk
Clinical/radiological Age ,3 years7 20 47
Metastatic disease4 20
Post-surgical residual disease .1.5 cm2 20
Histology Large-cell medulloblastoma6 9 10
Severe and diffuse anaplasia6 9 10
Biology MYC gene amplification9 17
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lumbar puncture (currently undertaken at least
15 days after surgery) has been shown to be more
reliable than ventricular CSF for staging purposes.22
The SIOP group define CSF involvement as the
unequivocal identification of tumour cells, either
on cytological grounds or with a combination of
cytological and immunocytochemical features.
The Chang T-staging classification23 that con-
siders local tumour invasiveness and size at
diagnosis is no longer used as several studies have
failed to demonstrate its prognostic signifi-
cance.24 25 On the other hand, the COG and SIOP
groups accept the likely prognostic importance of
achieving a gross total or near gross total surgical
excision,24 although the evidence for this is by no
means convincing. Residual disease is best demon-
strated by post-operative MRI imaging performed
within 72 h of surgery, after which time post-
operative changes render interpretation of residual
disease difficult.
Thus, as regards established prognostic variables,
patients with medulloblastoma are generally
divided into three groups: (1) standard risk
(SIOP) or average risk (COG) patients – those at
least 3 years of age without evidence of metastatic
spread and having (1.5 cm2 (maximum cross-
sectional area) of residual disease after surgery;
(2) high risk patients aged>3 years – patients with
evidence of CSF spread (M1 to M3) and/or those
with less complete resection; and (3) patients aged
,3 years at diagnosis.
Molecular markers offer significant potential for
improved therapeutic stratification of medulloblas-
toma patients, and a major feature of current
studies is the prospective evaluation of the prog-
nostic importance of markers of Wnt/Wg signal-
ling pathway activation and others referred to
above. The combined assessment of relationships
between molecular, histopathological and clinical
stratification markers in large clinical trials will be
critical to the development of improved staging of
medulloblastoma.
TREATMENT
General issues
The standard therapeutic approach for medullo-
blastoma consists of complete or near complete
surgical resection followed by post-operative radio-
therapy. The propensity of this tumour to spread
via the CSF pathways led to the early adoption of
CSRT. Attempts to omit the cranial or spinal
component of radiotherapy have resulted in an
unacceptable rate of supratentorial and/or spinal
failure.26 27
Surgery
Surgery remains a fundamental component of
treatment, particularly given the possible prognos-
tic importance of the degree of surgical excision.
Modern surgical techniques such as computer
assisted neuronavigation have allowed complete
or near complete tumour resection in a large
majority of cases. Furthermore, improvements in
neurosurgical care and the use of perioperative
dexamethasone have led to a reduction in surgical
mortality to well under 5%. A particular post-
operative problem is the so-called posterior fossa
syndrome (akinetic mutism) which occurs in up to
20% of patients and is characterised by mutism,
limb weakness, cranial nerve palsies, personality
changes and involuntary movements. The cause is
unclear, although this syndrome seems to mainly
occur when surgery involves the inferior cerebellar
vermis, and it particularly affects very young
children. Mutism and associated problems gener-
ally improve, although recent evidence suggests
that a significant proportion of survivors have
demonstrable speech deficit such as dysarthria,28
with a number having persistent ataxia, cognitive
dysfunction or cranial nerve deficits.
Radiotherapy
The optimum delivery of CSRT is a major
challenge in radiation planning, for example
ensuring an accurate dose to the junction of the
cranial and spinal components. Currently, a three-
dimensional conformal approach to radiation
therapy is used in most centres to deliver radiation
to the posterior fossa in order to limit the radiation
dose to the supratentorial brain29 (fig 3). In
addition, there is increasing interest in the use of
Figure 2 Wnt/Wg pathway activation is associated with a favourable outcome in
medulloblastoma. (A) Immunohistochemical analysis using an anti-b-catenin antibody
showing examples of strong combined cytoplasmic and nuclear reactivity (A1) and
cytoplasmic, non-nuclear staining (A2). (B) Kaplan–Meier overall survival curves for
children with b-catenin nucleo-positive and nucleo-negative medulloblastomas (data
previously reported in Ellison et al19). Photomicrographs kindly provided by Professor
David Ellison.
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so-called intensity modulated radiation therapy
(IMRT) for treating the posterior fossa. This uses
multiple fields defined by a computer generated
planning system. IMRT has been shown to be
associated with better sparing of structures such as
the cochlea and the hypothalamic–pituitary axis.30
In a few centres, principally in North America,
proton beam therapy is used to treat children with
medulloblastoma.31 The unique physical nature of
proton beams allows extremely tight dose distribu-
tions, which may be beneficial as regards the
posterior fossa and spinal components of radio-
therapy.
Historically the entire posterior fossa has been
irradiated, but it is unclear whether this is
necessary. Single institution pilot series have
demonstrated local control rates using a volume
limited to the tumour bed comparable with those
achieved with whole posterior fossa radiation
therapy.32 33 This is being further tested in the
current randomised COG trial for standard risk
medulloblastoma.
Finally, in Europe there has been much recent
interest in the use of hyperfractionated radio-
therapy using twice-daily fractions that can
theoretically increase the dose to the tumour
without an increase in the late effects to normal
nervous tissue. A French group has evaluated this
approach in an observational study of standard risk
patients with excellent tumour control.34
Subsequently, this technique was compared to
conventional radiotherapy in the recently com-
pleted HIT SIOP PNET 4 randomised controlled
trial, the results of which are awaited.
Quality control of radiation therapy
Numerous reports have demonstrated that close
attention to the quality of radiation therapy is
critical to the successful management of medullo-
blastoma. For example, several series have shown
an increased rate of subfrontal failures in patients
who have received suboptimal radiation to the
cribriform plate.35 The frequency of protocol
deviations and their adverse effects on outcome
have led to the mandatory central review of
radiotherapy planning in current COG and SIOP
studies. CT based simulation is now the standard
method, with several centres using so-called MRI-
CT fusion in which the patient’s MRI images are
overlaid with the CT planning scan to further
enhance the quality of radiation therapy. Delays in
completing radiation therapy have also been
associated with an increase rate of treatment
failure, as demonstrated in the recent SIOP PNET
3 trial.36
Chemotherapy
There is now widespread acceptance of the benefit
of chemotherapy in the management of medullo-
blastoma, which is clearly a chemosensitive
tumour, as demonstrated in several phase II
studies. A variety of different drugs and drug
combinations have been investigated in phase III
studies, including lomustine (CCNU), the plati-
num derivatives (cisplatin and carboplatin), etopo-
side, and alkylating agents such as
cyclophosphamide.
Similar first generation randomised studies were
conducted by the CCG and SIOP in which radio-
therapy alone was compared to radiotherapy
followed by chemotherapy (CCG: CCNU, vincris-
tine and prednisone; SIOP: CCNU and vincristine).
No statistical differences in survival between the
two treatment groups as a whole were seen,
although there was clear benefit for a subset of
patients with high-stage disease.37 38 Subsequent
studies have explored the timing of chemotherapy
in relation to radiotherapy and also the use of new
drug combinations in both high and standard risk
patients. The SIOP group explored the use of
chemotherapy before radiotherapy in both the
SIOP 2 and PNET 3 studies on the basis that
chemotherapy penetration into the tumour may be
optimal just after surgery when the blood–brain
barrier is disrupted and also because the myelo-
suppression associated with chemotherapy is
greater following spinal radiotherapy. The SIOP
PNET 3 study showed a significant improvement
in 3-year event free survival (EFS) (79% vs 64%) for
patients with standard risk medulloblastoma trea-
ted with moderately intensive pre-irradiation
chemotherapy when compared to those treated
with radiotherapy (35 Gy CSRT) alone.39 On the
other hand, the German HIT 91 study showed a
survival advantage for those patients with stan-
dard risk medulloblastoma receiving post-radiation
Packer chemotherapy (see below) as opposed to
those receiving a pre-radiotherapy chemotherapy
regimen.40
STANDARD/AVERAGE RISK MEDULLOBLASTOMA
Following the first generation studies, and recog-
nising the importance of tumour staging in
determining outcome, groups such as CCG, POG
and SIOP conducted a series of national and
Figure 3 Radiotherapy plan for conformal treatment of the whole posterior fossa (image
kindly provided by Dr Nicki Thorp).
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international studies on standard risk medulloblas-
toma. The principle aims of these trials were to
examine the benefits of chemotherapy in improv-
ing survival and explore the potential of using
chemotherapy to enable a reduction in the dose of
CSRT.
A POG/CCG study showed reduced survival in
children with standard risk medulloblastoma
receiving reduced dose CSRT (23.4 Gy) as com-
pared to those receiving standard dose CSRT
(36 Gy).41 Investigators in North America contin-
ued to explore the use of reduced dose CSRT, but
with the administration of chemotherapy follow-
ing radiotherapy. In this respect, the most widely
used treatment was introduced in the early 1980s
by Packer and consists of reduced dose CSRT
(23.4 Gy) with eight doses of concomitant weekly
vincristine followed by up to eight cycles of
chemotherapy with a combination of cisplatin,
CCNU and vincristine. Excellent initial results25
were confirmed in a CCG group-wide study with a
5-year progression free survival (PFS) of 79%.42 This
regimen was carried forward to the randomised
COG study A9961, which compared two adjuvant
chemotherapy arms (CCNU, cisplatin and vincris-
tine versus cyclophosphamide, cisplatin and vin-
cristine) given following reduced dose CSRT with
vincristine. For all patients, 5-year EFS was 81%
with no significant difference in survival between
the two treatment arms.21 As a result, reduced
radiotherapy (23.4 Gy CRST) with a posterior
fossa dose of 54–55.8 Gy followed by Packer
chemotherapy or modifications thereof is now
generally regarded both in North America and
Europe as standard therapy for standard risk
patients, and forms the basis for forthcoming
group-wide trials. A further reduction in the dose
of CSRT to 18 Gy is being investigated in the
current COG study for younger children with
standard risk medulloblastoma.
RESIDUAL DISEASE
Approaches to the management of patients with
significant post-operative residuum vary, with the
COG group treating patients according to high risk
protocols. There is, however, increasing interest,
certainly in Europe, of so-called second look
surgery in medulloblastoma, as in other childhood
brain tumours, in order to obtain maximum
surgical clearance. Such an approach was sup-
ported in the recent SIOP PNET IV trial where a
second operation potentially enabled a patient to
be downgraded to standard risk.
METASTATIC MEDULLOBLASTOMA
As opposed to standard risk disease, metastatic
medulloblastoma remains a tumour with poor
prognosis and relatively little progress has been
made in improving outcome. Standard treatment
consists of surgical excision of the primary tumour
followed by conventional radiotherapy with doses
of 35–36 Gy to the craniospinal axis together with
a boost of 18–20 Gy to the posterior fossa. In
addition, further boosts to sites of metastatic
disease are generally administered.
Chemotherapy is generally accepted as having an
important role in the treatment of metastatic
medulloblastoma, although this has not been
definitely proven in phase III studies and the
optimal chemotherapy regimen has yet to be
defined. Despite the use of chemotherapy, various
large multicentre studies have reported survival
figures of between 30% and 40% for patients with
M2/M3 status at diagnosis.20 42 43
More encouraging results have come from the as
yet unpublished North American study, POG-
9031, in which patients received radiotherapy
together with conventional chemotherapy. For
metastatic patients, 5-year EFS was over 60%.44
Similarly good results for metastatic patients were
noted in the St Jude Medulloblastoma-96 trial in
which children received four cycles of cyclopho-
sphamide-based, dose-intensive chemotherapy fol-
lowing radiotherapy.16 A 65% 5-year EFS for 33
patients with M2/M3 disease was observed (Gajjar,
personal communication). It is of note, however,
that both studies used higher CSRT doses of 40
and 39 Gy, respectively. These results may indicate
a dose–response effect for radiotherapy doses above
35–36 Gy, although there must be concern regard-
ing worsening of the neuro-psychological sequelae
of these higher CSRT doses.
Altered radiotherapy fractionation schedules,
such as twice daily radiotherapy, can theoretically
increase the dose to tumour without an increase in
the dose to normal nervous tissue. Very encoura-
ging data have recently come from the Milan
group, who use a programme of high dose
sequential chemotherapy followed by hyperfrac-
tionated accelerated radiotherapy (HART) in chil-
dren with metastatic medulloblastoma.45 A 3-year
EFS of 75% has been reported for 24 patients. A
current UK study of patients with metastatic
medulloblastoma is testing the use of up-front
HART followed by Packer chemotherapy.
The COG group have recently completed a phase
1 study for patients with high risk disease based on
the use of radiotherapy given with concomitant
carboplatin, a chemotherapy agent with radio-
sensitising properties. Early results are encouraging
with a 3-year EFS of over 60% for metastatic
patients46 and this study now forms the basis of a
recently opened phase III randomised trial that will
test the addition of 13-cis-retinoic acid. Other
groups are investigating the use of high dose
chemotherapy with autologous haematopoietic
progenitor cell rescue in high risk medulloblas-
toma.
MEDULLOBLASTOMA IN VERY YOUNG CHILDREN
The management of the very young child with
medulloblastoma is one of the greatest challenges
in paediatric oncology. It is clearly extremely
difficult to strike a balance between improving
survival and achieving acceptable long-term neu-
ropsychological sequelae. Following the acceptance
that CSRT used as standard therapy in older
Best practice
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patients produces unacceptable and devastating
neuropsychological sequelae in very young children,
chemotherapy based strategies were developed to
delay or avoid the use of CSRT. The cut-off at which
CSRT is avoided varies between 3 and 6 years of age
according to the historical and philosophical per-
spectives of individual institutions and national
groups. Initial studies included the so-called Baby
Brain protocols in which prolonged, relatively
tolerable chemotherapy was given with the aim of
delaying or, as in the case of French and UK groups,
completely avoiding radiotherapy. This approach
was partly successful. Both the French and UK Baby
Brain protocols gave EFS rates of around 30% with
the French group showing a clear distinction in
outcome for patients with and without complete
surgical excision.47 Furthermore, the French group
developed a successful salvage strategy based on
myeloablative chemotherapy followed by focal
radiotherapy in those patients relapsing off their
Baby Brain protocol.48 A German group have based
treatment on moderately intensive chemotherapy
that includes intraventricular methotrexate given
via an in-dwelling reservoir. It is argued that giving
chemotherapy intraventricularly can overcome the
problems associated with the blood–brain barrier
that limits systemic delivery of chemotherapy to the
CNS. In the first German study of 43 patients, 17
who had a complete surgical resection and no solid
metastases had a very encouraging 82% PFS.7
Survival for patients with residual disease after
surgery (5-year PFS of 50%) or with solid metastases
(5-year PFS of 33%) was inferior. Patients who were
not irradiated had acceptable neuropsychological
outcome on formal direct testing. It is of great
importance that this study showed a clear survival
advantage for those 20 patients with desmoplastic
histology (5-year PFS of 85%) as opposed to the 23
children with classic histology (5-year PFS of 34%).
The prognostic importance of desmoplasia was also
seen in an analysis of patients entered into the
original UK Baby Brain protocol.8
Other groups have used high dose chemotherapy
with stem cell rescue. Encouraging early results (4-
year PFS of 68%) have been seen from an American
study that was based around three sequential
courses of myeloablative chemotherapy with thio-
tepa and carboplatin (Ashley, personal commu-
nication).
The increased ability to deliver tightly controlled
radiotherapy using conformal approaches without
the supratentorial structures (eg, limbic system
and cortical hemispheres) receiving a significant
dose of radiation has led to renewed recent interest
in using posterior fossa radiotherapy in up-front
strategies for very young children. Neuropsy-
chological testing seems to support this method.
In this respect, the current UK approach is based
around the use of moderately intensive chemother-
apy with cyclophosphamide and carboplatin fol-
lowed by posterior fossa radiotherapy. Early results
suggest a survival rate of around 50–60% for non-
metastatic patients.
Thus, although survival remains worse than in
older patients in whom CSRT is a standard part of
treatment, the outlook for young children appears
to be improving. The main priorities should be to
develop a clear understanding of prognostic factors
in infant medulloblastoma and to strengthen
international collaboration that will hopefully lead
to transatlantic studies for this poor risk group. In
addition, the design of future studies must consider
quality of survival as a vital outcome measure.
LATE EFFECTS OF THERAPY
It is now clear that a high proportion of survivors
of medulloblastoma have significant long term
sequelae. Although the aetiology is mutifactorial, it
is probable that the most important factor in the
pathogenesis of these sequelae is the use of CSRT.
Other factors are, however, clearly important, and
it is interesting to note that Bull et al showed that
for patients entered into the SIOP PNET 3 study,
the addition of chemotherapy to CSRT was
associated with a significant decrease in health
status.49
The decline in neurocognitive function has been
shown in a number of studies such as that from
Hoppe-Hirsch et al in which 10 years after treat-
ment 75% of survivors had an IQ of below 80.50
Other studies have demonstrated poor general
functional outcomes including social and educa-
tional difficulties in survivors. In addition, follow-
ing higher doses (35 or 36 Gy) of CSRT the
majority of survivors suffer significant growth and
endocrine dysfunction, predominately due to
irradiation of the hypothalamic-pituitary axis
together with the effects of whole spine radio-
therapy.51
The effect of treatment on neuropsychological
outcome appears to be particularly severe in young
children, especially those less than 7 or 8 years of
age.49 51 52 Lower CSRT doses (23.4 Gy), currently
used for standard risk medulloblastoma, continue
to show an adverse affect on intellectual develop-
ment which, however, is not as severe as that
seen with conventional radiation therapy doses.53
Silber et al estimated that there was an approx-
imate 4 point per year decline in IQ for children
treated with 24 Gy CSRT compared with an
approximate 8 point per year decline for those
receiving 36 Gy.54
It is now recognised in both Europe and North
America that a prospective assessment of quality of
survival should be included in clinical trials for all
brain tumour types including medulloblastoma.
Although direct neuropsychological evaluation,
such as formal IQ testing, has clear benefits, this
is logistically challenging in the context of group-
wide studies. Thus, in the UK and Europe, the
focus is now on assessment by indirect measures
such as the Health Utilities Index, the Strength and
Difficulties Questionnaire and a quality of life
measure, which can be incorporated into an easily
completed parent or patient questionnaire.
Best practice
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RELAPSE
Un-irradiated young children may be successfully
treated as has been clearly demonstrated for
patients relapsing off the French Baby Brain
Study.48 For previously irradiated patients with
medulloblastoma, the predominant site (80%) of
relapse is distant leptomeningeal, either alone or in
combination with relapse at the primary site. For
such patients receiving conventional therapy fol-
lowing prior radiotherapy, the prognosis at relapse
is extremely poor with only around 2% of patients
surviving. Since the 1990s a number of studies have
suggested that a significant proportion of patients
may be cured using a strategy based on myeloa-
blative chemotherapy with stem cell rescue. Early
reports from the USA suggested that up to 30% of
such patients might be cured,55 although it appears
that these are a very select group of patients. More
population based studies such as the recently
completed UK relapsed PNET study and a large
German study of over 70 patients suggest that
under 5% to 10% of patients are cured using high
dose chemotherapy. Those patients who may
particularly benefit from this approach include
those who have an isolated relapse that is amen-
able to second surgery with or without radio-
therapy and those who achieve complete remission
prior to the administration of high dose che-
motherapy.
FUTURE DIRECTIONS
Current and future studies will continue to explore
modification of both radiotherapy and chemother-
apy as described above in an attempt to reduce the
side effects of treatment in favourable risk patients
and to increase survival in high risk patients,
particularly those with metastatic disease. It is
likely that the use of intraventricular chemother-
apy will be investigated in older children as well as
in infants.
It is clear, however, that recent advances in our
understanding of tumour biology and pathology
have necessitated a re-evaluation of prognostic
factors. The SIOP group aims to develop new
studies, with therapy stratified according to
biological as well as clinical factors. For example,
b-catenin positivity may define a good risk group,
for whom the burden of chemotherapy could be
reduced. Similarly, the identification and validation
of markers associated with a poor outcome, such as
MYC amplification, will aid the delineation of poor
risk groups. As a prelude to this work, a study is
about to begin to test the feasibility of pre-
treatment biological characterisation of individual
tumours.
Furthermore, our new understanding of the
biology of medulloblastoma will potentially lead
to the development of novel rationally designed
small-molecule chemotherapeutic agents designed
to target tumour-specific pathways.
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